Cost Savings Related to Biosimilars

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

Now Viewing

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Ryan Haumschild asks Vibeke Strand to discuss biosimilar cost savings and who is driving and benefiting from them.

Strand says patients should benefit, but it is unclear whether they do, given the health care system maze involving pharmacy benefit managers (PBMs) that determine payer coverage. Providers have little insight into PBM processes and formulary decision-making. Limitations exist even with Medicare and Medicaid. With multiple adalimumab (Humira) biosimilars at varying discounts, it is unknown how to translate that into patient cost savings at the point of prescribing. Greater transparency around cost impacts for patients is needed.

Haumschild agrees the value proposition around cost is opaque for patients. Although payers and providers in value-based contracts may benefit from lower expenses, it is difficult to demonstrate financial benefits directly reaching patients facing financial toxicity and adherence challenges. More clarity around patient costs is needed.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.